Cardiovascular diseases and cancer are two of the most common causes of death worldwide. Bayer scientists are working on new, targeted therapies in both areas to ensure that patients can be treated more effectively in future. In the case of heart patients with kidney failure, for example, they are looking at the interactions between the heart and the kidneys to develop new active ingredients that protect both organs at the same time. In tumor therapy, too, therapeutic approaches can now be tailored more precisely to the needs of the individual patient thanks to personalized medicine. Researchers at BayerHealthCare want to collaborate with partners to develop a specific diagnostic test for each new targeted therapy so that in the future every patient should receive treatment that is optimally suited to his or her clinical picture.
Researchers at Bayer HealthCare are focusing on developing cancer drugs directed at the specific targets that are responsible for the malignant behavior of tumor cells. In parallel, they are working with partners to develop specific diagnostic tests that can identify the presence of these targets in an individual patient’s tumor. Their goal is to advance more targeted therapies with companion diagnostics so that in the future each cancer patient can receive the treatment that is best suited to his or her disease.
Read part 1 “Better Living with Cancer“
A weak heart damages the kidneys – and weak kidneys damage the heart. Successful treatments therefore have to incorporate several strategies. With new substances currently under development, researchers atBayer HealthCare are now protecting both organs at the same time.
Read part 2 “Dual Protection“